Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.32 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.32 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.32 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.32 |
| ▸ | APLNR | P35414 | 4/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.32 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL898935 | 0.93 | NR3C2 (0.36) | MAPK14P2RX7MAPK11NR3C2PDE7A | |
| SCHEMBL899820 | 0.89 | WNT3A (0.34) | MAPK14MAPK13MAPK12MAPK11APLNR | |
| SCHEMBL898920 | 0.89 | NR3C2 (0.37) | MAPK14MAPK13MAPK12MAPK11NR3C2 | |
| SCHEMBL898515 | 0.89 | NR3C2 (0.32) | P2RX7NR3C2 | |
| SCHEMBL899021 | 0.84 | NR3C2 (0.34) | P2RX7NR3C2 | |
| SCHEMBL899181 | 0.83 | NR3C2 (0.31) | P2RX7NR3C2 | |
| SCHEMBL899241 | 0.83 | PDE2A (0.34) | P2RX7LMNAGAAKMT2A | |
| SCHEMBL898213 | 0.83 | NR3C2 (0.35) | MAPK14NR3C2PDE7A | |
| SCHEMBL899633 | 0.82 | NR3C2 (0.35) | MAPK14MAPK13MAPK12MAPK11NR3C2 | |
| SCHEMBL898925 | 0.80 | NR3C2 (0.34) | MAPK14MAPK13MAPK12MAPK11NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621907-A1 | FUNGICIDAL IMIDAZOLES | E.I. Du Pont De Nemours And Company (US) | 2013-08-07 | — | — | EP | claimed |
| US-20130143929-A1 | FUNGICIDAL IMIDAZOLES | EI DU PONT DE NEMOURS AND COMPANY (US) | 2013-06-06 | — | — | US | claimed |
| WO-2012044650-A1 | FUNGICIDAL IMIDAZOLES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-04-05 | — | — | WO | claimed |
| US-20130143929-A1 | FUNGICIDAL IMIDAZOLES | EI DU PONT DE NEMOURS AND COMPANY (US) | 2013-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143929-A1 | FUNGICIDAL IMIDAZOLES | CYP1A1, CYP1B1, CYP2E1 | MAPK14 3555/4885P2RX7 961/4885MAPK13 3761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.